Scott Bizily - Apr 21, 2023 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal and HR Officer
Signature
/s/ August J. Moretti, Attorney-in-Fact for Scott Bizily
Stock symbol
FDMT
Transactions as of
Apr 21, 2023
Transactions value $
-$44,850
Form type
4
Date filed
4/25/2023, 06:44 PM
Previous filing
Mar 3, 2023
Next filing
Jun 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $30.2K +3.75K +177.81% $8.04 5.86K Apr 21, 2023 Direct F1
transaction FDMT Common Stock Sale -$75K -3.75K -64% $20.00 2.11K Apr 21, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -3.75K -6.67% $0.00 52.5K Apr 21, 2023 Common Stock 3.75K $8.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 13, 2022.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.